Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Boston Beer Company Inc (SAM) Price & Performance

Bristol-Myers Squibb CoTrade
Boston Beer Company IncTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Boston Beer Company Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.94 (market cap $129.94B), while Boston Beer Company Inc trades at $181.7 (market cap $1.86B). The key difference: Bristol-Myers Squibb Co is far larger — about 69.9× Boston Beer Company Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.

BMYSAM
Market Cap
$129.94B$1.86B
Sector
HealthConsumer Staples
52-Week High
$65.89$260.05
52-Week Low
$42.60$161.08
Enterprise Value
$163.92B$1.63B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.

The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.

Boston Beer Company Inc

Boston Beer Company (SAM) trades at $181.95, up 0.53% with bearish technical signals despite recent earnings volatility. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.99, but faces profitability challenges with negative net income margin (-3.64%) and ROE (-8.61%). Recent Q2 2026 earnings missed estimates at $3.65 vs. $4.83 expected, while operating cash flow remains strong at $270M in 2025. Analyst sentiment is cautious with 72% hold ratings amid declining volumes and competitive pressures.

Outlook remains challenging with weak demand impacting core brands, though spirits-based RTD growth and margin improvements offer some support. The consensus price target of $207.33 suggests 14% upside potential, but investors face risks from sustained volume declines, rising marketing costs, and negative earnings growth projections for 2026. The stock's current technical position near pivot point resistance at $182 requires monitoring for breakout confirmation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Boston Beer Company Inc

Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.

Read more on SAM